| Property | Value |
|---|
|
?:abstract
|
-
Objectives The Coronavirus19 (COVID19) pandemic continues to impose formidable challenges on healthcare services. The dramatic curtailment of endoscopy and CT colonography capacity has adversely impacted on timely diagnosis of colorectal cancer (CRC). We describe a COVID adapted pathway rapidly implemented to mitigate risk and maximise cancer diagnosis in patients referred with symptoms of suspected CRC during the pandemic. Design The COVID adapted pathway integrated multiple quantitative faecal immunochemical tests (qFIT), to enrich for significant colorectal disease. CT with oral contrast was used to detect gross pathology. Patients reporting high risk symptoms were triaged to qFIT+CT and the remainder underwent initial qFIT. Prospective data collection comprised referral category, symptoms, blood results, medical history, time to first test, qFIT and CT results. Setting Tertiary colorectal unit which manages over 500 cancer patients annually. Participants All patients referred as urgent suspicious of cancer (USOC) were included. Overall 422 patients (median age 64 years, 220 females) were triaged using this pathway. Main outcome measures Outcomes comprised cancer detection frequency. Results Compared to the same time period (1st April to 31st May) in 2017 to 2019, we observed a 43% reduction in primary care referrals with suspected CRC (1071 referrals expected reducing to 609). Overall 422 patients (median age 64 years, 220 females) were triaged using this pathway. Most (84.6%) were referred as USOC. Of the 422 patients, 202 (47.9%) were triaged to CT and qFIT, 211 (50.0%) to qFIT only, eight (1.9%) to outpatient clinic, and one to colonoscopy. Fifteen (3.6%) declined investigation and seven (1.7%) were deemed unfit. We detected 13 cancers (3.1%); similar to the mean cancer detection rate from all referrals in 2017-2019 (3.3%). Conclusions The response to the COVID19 pandemic resulted in a marked reduction in referrals and cessation of key diagnostic services. Although this COVID adapted pathway mitigated the adverse effects on diagnostic capacity, the overall reduction in expected diagnoses is very substantial. It is clear that the adverse impact of measures taken to constrain the pandemic will lead to many undetected cancers due to the decrease in referrals. Trial registration Not applicable
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
-
10.1101/2020.11.23.20236778
|
|
?:doi
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/861854f5c076f3f409772605ffc2fde2e1817b4a.json
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Assessment of effectiveness of a COVID-adapted diagnostic pathway for colorectal cancer to mitigate the adverse impact on investigation and referrals
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}